氯吡格雷与阿司匹林治疗冠心病的效果比较

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the effect of Clopidogrel and Aspirin in the treatment of coronary heart disease.Methods A retrospective analysis was conducted on 100 patients with coronary heart disease treated in Yangjiang Traditional Chinese Medicine Hospital from January 2018 to January 2020.According to the treatment drugs,they were divided into two groups: Clopidogrel group (n=50) and Aspirin group (n=50).The clinical efficacy,coagulation functions and adverse reactions of the two groups were statistically analyzed.Results The total effective rate of the Clopidogrel group was 94.0% (47/50),which was higher than the Aspirin group of 62.0% (31/50),the difference was statistically significant (P＜0.05).Comparison of coagulation function indexes before treatment between the two groups showed no statistically significant difference (P＞0.05).After treatment,the platelet aggregation rates of the two groups were lower than those before treatment,and the activated partial thrombin time (APTT) and prothrombin time (PT) were shorter than those before treatment,with statistically significant differences (P＜0.05).The platelet aggregation rate of Clopidogrel group after treatment was lower than that of Aspirin group,and APTT and PT were shorter than those of Aspirin group,with statistically significant differences (P＜0.05).The total incidence of adverse reactions in the Clopidogrel group was 8.0% (4/50),which was lower than 36.0% (18/50) in the Aspirin group,with statistically significant difference (P＜0.05).Conclusion The clinical effect of Clopidogrel in patients with coronary heart disease is better than Aspirin,with fewer adverse reactions,which is worthy of clinical application.

Key words： Coronary heart disease Clopidogrel Aspirin Clinical effect Coagulation function Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIU Hong-wei
	CHEN Xiao-chun
	LIANG Zhi-hao

Cite this article:

QIU Hong-wei,CHEN Xiao-chun,LIANG Zhi-hao. Effect comparison of Clopidogrel and Aspirin in the treatment of coronary heart disease[J]. 中国当代医药, 2021, 28(1): 81-83.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I1/81

[1]	张心悦，黄薰莹，哈略，等.艾灸对氯吡格雷抵抗冠心病患者睡眠质量的影响评估[J].北京中医药大学学报，2020，43（1）：84-88.
[2]	黎国德，许庆波，韩克栋.MTHFR 基因多态性对冠心病合并高血压患者氯吡格雷耐受性的影响[J].广东医学，2020，41（1）：91-96.
[3]	刘国华，杨兆兴，丁立新，等.氯吡格雷和阿司匹林治疗老年冠心病患者的临床效果评估[J].河北医药，2020，42（1）：74-77.
[4]	李强，陆士娟，钟江华，等.遗传因素对冠心病患者氯吡格雷血小板反应差异的影响[J].实用医学杂志，2019，35（22）：3492-3497.
[5]	蒋端，李静.多重用药对冠心病患者发生氯吡格雷抵抗的影响研究[J].中国全科医学，2019，22（30）：3709-3713.
[6]	周岩，李莹，张法英，等.复方丹参汤辅助氯吡格雷治疗冠心病的血流变、血流动力学与心功能观察[J].世界中医药，2019，14（12）：3247-3251.
[7]	崔英慧.不同剂量硝酸甘油联合氯吡格雷治疗冠心病心绞痛的比较研究[J].河北医药，2019，41（17）：2678-2680，2684.
[8]	冯艳林，李毅，马瑞，等.老年冠状动脉粥样硬化性心脏病合并糖尿病患者经皮冠状动脉介入术后应用替格瑞洛和氯吡格雷的临床疗效比较[J].中国医药，2020，15（2）：178-182.
[9]	郭玉梅，张琳，李海洲.血小板微小RNA-223 和微小RNA-21 对冠心病患者经皮冠状动脉介入治疗后氯吡格雷抵抗的预测价值[J].临床内科杂志，2020，37（1）：28-31.
[10]	杨雅薇，周菁，姚磊，等.桃红四物汤联合氯吡格雷对稳定型冠心病病人PCI 术后抗血小板的疗效评估[J].中西医结合心脑血管病杂志，2019，17（23）：3649-3653.
[11]	杨雅薇，章伟，秦永文，等.氯吡格雷引起纯红细胞再生障碍性贫血1 例[J].国际心血管病杂志，2019，46（5）：315-317.
[12]	杜梦阳，宋莹，许晶晶，等.钙离子拮抗剂对冠心病行经冠状动脉介入术后联合氯吡格雷治疗预后的影响[J].南昌大学学报（医学版），2019，59（3）：45-50，55.
[13]	谢文剑，黄贝贝，殷蒨，等.lncRNA 在冠心病氯吡格雷抵抗患者中的差异性表达[J].中南大学学报（医学版），2019，44（1）：9-13.
[14]	车忠应，张珍，刘亭亭.阿托伐他汀联合氯吡格雷对冠心病心绞痛患者心功能的影响[J].中国药物与临床，2019，19（16）：2808-2809.
[15]	刘倩倩，王海明，瞿秀敏，等.血小板参数、血脂水平与冠心病PCI 术后氯吡格雷抵抗的相关性[J].现代仪器与医疗，2019，25（6）：53-56.
[16]	蒋萍，宋莹，许晶晶，等.血尿酸与经皮冠状动脉介入治疗后服用氯吡格雷患者血小板反应性的相关性研究[J].中国循环杂志，2019，34（7）：658-663.